Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study
暂无分享,去创建一个
S. Sacchi | A. Guarini | C. Minoia | L. Marcheselli | R. Ria | G. Mele | F. Morabito | M. Gentile | I. Vincelli | P. Musto | A. Palumbo | S. Pozzi | R. Marcheselli | A. Bari | C. Mazzone | A. Corso | F. Cocito | E. Rivolti | S. Badiali